Myeloproliferative Neoplasms (MPNs) [Excluding CML]

Primary Myelofibrosis (PMF)

- Previously enrolled in HEMMPD0020 or HEMMPD0018
  - HEMMPD0031
    - Phase II Luspatercept (ACE-536) in Myeloproliferative Neoplasm-Associated Myelofibrosis & Anemia +/-
      - PI: Gilead
  - HEMMPD0033
    - Extended Access Methylotinib in PMF /Post-polycythemia Vera /Post-Essential Thrombocytemia Myelofibrosis
      - PI: Gilead Pending

- Progressed /Intolerant on JAK
  - HEMMPD0030
    - Phase II Pacritinib in Myeloproliferative Disorders Previously Treated with Ruxolitinib
      - PI: Gilead CTI Biopharma

Aggressive Systemic Mastocytosis/ Mast Cell Leukemia

- CD30-
  - HEMMPD0034
    - Phase II Avapritinib (BLU-285) KIT Mutation-targeted TKI in Advanced Systemic Mastocytosis
      - PI: Gilead Pending
  - 1st Priority

Chronic Neutrophilic Leukemia (CNL) and Atypical Chronic Myeloid Leukemia (CML)

- HEMMPD0022
  - Phase II Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML
    - PI: Gilead
  - 2nd Priority

- HEMMPD0027
  - Phase I BLU-285 in Advanced Systemic Mastocytosis (advSM) & Relapsed /Refractory Myeloid Malignancies
    - PI: Gilead Blueprint Medicines Corp
  - 2nd Priority

- HEMMPD0029
  - Phase I DCC-2618 in Advanced Malignancies
    - PI: Gilead Deciphera Pharmaceuticals
  - 3rd Priority

FGFR1 Rearrangement

- HEMMPD0028
  - Phase II INCB054828 in Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
    - PI: Gilead Incyte Corporation

KEY

- Pending
- Open for Enrollment
- Optional Path
- Extension Study
- Immunotherapy
- Link
- Trial Posting
- Observational Study
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu